Biohaven Entered into an Exclusive License and Research Agreement with KU Leuven to Develop and Commercialize BHV-2100 for Chronic Pain Disorders
Shots:
- KU Leuven to receive an up front & is eligible to receive additional development, regulatory, and commercialization milestones along with royalties on net sales of products that emerges from the collaboration
- Under the collaboration, Biohaven gets exclusive global rights to develop, manufacture, and commercialize KU Leuven's BHV-2100 (TRPM3 antagonists) which is expected to enter in clinical development in H1’23 for neuropathic pain
- Biohaven will be responsible to support basic and translational research of TRPM3 in pain and other disorders. Additionally, BHV-2100 showed promising efficacy in preclinical pain models and will move towards P-I studies
Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com